Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367133 | 0.83 | LMNA (0.68) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL6578237 | 0.82 | LMNA (0.58) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL365988 | 0.81 | LMNA (0.65) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL2830638 | 0.81 | LMNA (0.73) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL29415206 | 0.81 | LMNA (0.65) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL15610852 | 0.81 | LMNA (0.65) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL15024639 | 0.79 | LMNA (0.80) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL368130 | 0.79 | LMNA (0.78) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL14023821 | 0.79 | LMNA (0.62) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL3915318 | 0.78 | LMNA (0.68) | LMNATHRBCYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-114478489-B | Preparation method and application of fluorine-19 modified nitroimidazole compound and derivative thereof | 中国科学院精密测量科学与技术创新研究院 | 2023-04-28 | — | — | CN | disclosed |
| CN-114478489-A | Preparation method and application of fluorine-19 modified nitroimidazole compound and derivative thereof | 中国科学院精密测量科学与技术创新研究院 | 2022-05-13 | — | — | CN | disclosed |
| US-10357577-B2 | Bacterial nitroreductase enzymes and methods relating thereto | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-07-23 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
| US-20080274057-A1 | Staudinger Reaction in Imaging and Therapy and Kits for Use in Imaging and Therapy | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-11-06 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| EP-0775117-B1 | FLUORINATED 2-NITROIMIDAZOLE ANALOGS FOR DETECTING HYPOXIC TUMOR CELLS | STANFORD RES INST INT (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5721265-A | FOR MAGNETIC RESONANCE IMAGING | SRI INTERNATIONAL (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0775117-A1 | FLUORINATED 2-NITROIMIDAZOLE ANALOGS FOR DETECTING HYPOXIC TUMOR CELLS | SRI INTERNATIONAL (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004249-A1 | FLUORINATED 2-NITROIMIDAZOLE ANALOGS FOR DETECTING HYPOXIC TUMOR CELLS | SRI INTERNATIONAL (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | LMNA 593/4885THRB 364/4885CYP2C19 4357/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | LMNA 1059/4885THRB 2933/4885CYP2C19 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.